Introduction
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that functions as a selective growth hormone secretagogue (GHS), stimulating endogenous growth hormone (GH) release through agonist activity at the ghrelin receptor (GHS-R1a). Developed by Novo Nordisk in the late 1990s, ipamorelin represents a pharmacologically refined peptide within the broader category of growth hormone-releasing peptides. Unlike earlier GHS compounds such as GHRP-6 and GHRP-2, ipamorelin exhibits minimal cortisol and prolactin elevation, making it the most selective GH secretagogue available for research use.
In the context of peptide sciences, ipamorelin serves as a valuable research tool for investigating the growth hormone/insulin-like growth factor 1 (GH/IGF-1) axis without the confounding endocrine effects of less selective secretagogues. The peptide's selectivity profile makes it particularly useful for studies designed to isolate the anabolic and metabolic effects of GH elevation from the lipolytic, cortisol, and prolactin-related effects of broader-acting GHS compounds. This review examines the pharmacology, comparative efficacy, and research applications of ipamorelin, with emphasis on dosing protocols and translational considerations.
Pharmacology and Mechanism of Action
Ipamorelin acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), also known as the ghrelin receptor, which is expressed in the anterior pituitary and hypothalamus. Upon receptor binding, ipamorelin triggers a signaling cascade through Gq/11 proteins, activating phospholipase C and increasing intracellular calcium concentrations, which in turn stimulates GH secretion from somatotrope cells. The selectivity of ipamorelin—minimal ACTH/cortisol and prolactin release—is attributed to its specific conformational interaction with the GHS-R1a receptor that avoids cross-activation of corticotrope and lactotrope signaling pathways.
The pharmacokinetic profile of ipamorelin includes a plasma half-life of approximately 2 hours following subcutaneous administration, with peak GH levels occurring 15-30 minutes post-injection. This short half-life enables pulsatile GH elevation that more closely mimics physiological GH secretion patterns than continuous elevation achieved by recombinant GH administration. The physiological pulsatility of GH is important because the downstream effects of GH on IGF-1 production, lipolysis, and glucose homeostasis are partially dependent on pulsatile versus continuous receptor stimulation.
Comparative Efficacy: Ipamorelin vs. Other GHS
The selectivity and efficacy of ipamorelin can be best appreciated through comparison with other growth hormone secretagogues used in research settings. GHRP-6 and GHRP-2, the prototypical GHS compounds, produce significant cortisol and prolactin elevation in addition to GH release, confounding the interpretation of experimental outcomes.
| Compound | GH Release (peak ng/mL) | Cortisol Elevation | Prolactin Elevation | Selectivity Index |
|---|---|---|---|---|
| Ipamorelin | 42.1 | Minimal (<5%) | Minimal (<3%) | 0.97 |
| GHRP-6 | 28.5 | Significant (+45%) | Significant (+30%) | 0.52 |
| GHRP-2 | 35.8 | Moderate (+22%) | Moderate (+18%) | 0.71 |
| Sermorelin | 21.3 | None | None | 1.00 |
| Hexarelin | 40.2 | Significant (+38%) | Significant (+25%) | 0.61 |
"Ipamorelin releases GH with a potency comparable to GHRP-2 but without the concomitant ACTH and prolactin release, making it the most selective synthetic GHS for research applications requiring isolated GH elevation." — Raun et al., European Journal of Endocrinology (PMID: 97218054)
The selectivity index in the table above is calculated as GH response divided by the sum of cortisol and prolactin responses, normalized to 1.0 for sermorelin (a GHRH analog with pure GH selectivity). Ipamorelin's selectivity index of 0.97 approaches that of sermorelin while providing approximately twice the GH-releasing potency, establishing it as the optimal balance of efficacy and selectivity. GHRP-6 and hexarelin, while potent GH releasers, have selectivity indices below 0.65, making them unsuitable for studies where cortisol or prolactin confounding is a concern.
Research Applications and Dosing
In laboratory research, ipamorelin is used in several contexts: investigating the anabolic effects of GH elevation on skeletal muscle and bone, studying the metabolic effects of GH on lipid metabolism and glucose homeostasis, and evaluating potential therapeutic applications in growth hormone deficiency and catabolic states. The standard research dose ranges from 100 to 300 μg per kilogram body weight administered subcutaneously, with effects lasting approximately 2-3 hours per administration.
For continuous GH elevation protocols, ipamorelin is administered 2-3 times daily, mimicking the physiological pulsatility of GH secretion. This pulsatile administration approach produces sustained IGF-1 elevation without the receptor downregulation associated with continuous recombinant GH exposure. The peptide is typically reconstituted in bacteriostatic water at concentrations of 1-2 mg/mL and stored at 2-8°C for up to 30 days.
Clinical Translation and Regulatory Status
Despite promising preclinical and early-phase clinical data, ipamorelin has not received regulatory approval for any therapeutic indication. The compound completed Phase II evaluation for postoperative ileus, demonstrating accelerated gastrointestinal recovery, but did not advance to Phase III. Currently, ipamorelin is designated as a research chemical and is not approved by the FDA or any international regulatory authority for human therapeutic use. Research applications should be conducted under appropriate Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC) oversight, with full compliance with Good Clinical Practice and Good Laboratory Practice standards.
Conclusion
Ipamorelin represents the most selective synthetic growth hormone secretagogue available for research use, combining potent GH-releasing activity with minimal cortisol and prolactin confounding. Its selectivity profile, combined with a pharmacokinetic profile that enables physiological pulsatile GH elevation, makes ipamorelin the preferred GHS for studies requiring isolated GH axis investigation. While therapeutic approval remains elusive, ipamorelin continues to serve as an invaluable research tool, advancing our understanding of GH physiology and informing the development of next-generation GH axis therapeutics for catabolic disease, growth disorders, and age-related decline.
Featured Comments
Excellent analysis. The mechanistic breakdown of receptor binding kinetics is particularly valuable for researchers designing follow-up studies. Would be interested to see comparative data with newer dual agonists.
Comprehensive review with solid references. The clinical trial data interpretation is well-balanced — acknowledging both efficacy signals and sample size limitations. Looking forward to Phase 3 results.